



Republic of the Philippines
Department of Health

CENTRAL OFFICE BIDS AND AWARDS COMMITTEE

COBAC RESOLUTION NO. 2021-078-A

15 March 2021

RECOMMENDING APPROVAL FOR THE AWARD OF CONTRACT FOR THE PROCUREMENT OF PREDNISONE / SVP NO. 2021-005/

WHEREAS, the Central Office Bids and Awards Committee (COBAC) - A received the request from the Disease Prevention and Control Bureau (DPCB) for the Procurement of Prednisone in accordance with Republic Act (RA) 9184 and its 2016 Revised Implementing Rules and Regulations (IRR) through the General Appropriations Act of 2021 with a Total Approved Budget for the Contract (ABC) of Forty Three Thousand Two Hundred Twenty Five Philippine Pesos (PhP43,225.00), to wit:

Item No.	Particular	Quantity	Unit	Total ABC (PhP)
1	Prednisone /	17,500 /	Tablet /	43,225.00 /

WHEREAS, the COBAC Resolution No. 2021-078 "Recommending Approval for the Use of Negotiated Procurement through Small Value Modality for the Procurement of Prednisone under SVP No. 2021-005", was approved;

WHEREAS, the Technical Working Group (TWG) was created through the issuance of Department Personnel Order (DPO) COBAC No. 2021-062 dated 19 February 2021;

WHEREAS, on 19 February 2021, the Request for Quotation (RFQ) was posted in the PhilGEPS and Department of Health (DOH) websites and in conspicuous places within the premises of the DOH for a continuous period of three (3) calendar days;

WHEREAS, the RFQ was sent to seven (7) prospective bidders listed below:

- 1) Metro Drug Inc. JV with Interpharma Holdings and Management Corp. (MDI JV with IHMC);
- 2) Roymed Pharmaceutical (RP);
- 3) Rilem Pharma Corp (RPC);
- 4) SGS Healthcare Co. (SGS);
- 5) Pomona Pharmaceutical Distribution (PPD); and
- 6) Bansan Pharma Distributor (BPD); and
- 7) L. Myerf Pharma Inc. (LMPI).

WHEREAS, pursuant to Annex "H" Section (V) (D) (8) (b) (ii), the BAC shall prepare and send RFQs to at least three (3) suppliers. Receipt of at least one (1) quotation is sufficient to proceed with the evaluation thereof;

WHEREAS, on 24 February 2021, the Submission and Opening of Quotations took place as scheduled at 9:00 A.M. at the COBAC Conference Room, DOH wherein one (1) prospective bidder submitted its quotation, namely, MDI JV with IHMC;

WHEREAS, the envelope, containing the eligibility and technical documents, was individually opened and the presence and validity of all the required documents were verified by the COBAC-A. Upon checking, MDI JV with IHMC was declared “ELIGIBLE” and was rated “PASSED” and its quotation was read out publicly and posted in the Abstract of Quotations, to wit:

Name of Company					MDI JV with IHMC
Remarks					ELIGIBLE / PASSED
ITEM NO.	Description	Qty.	Unit	TOTAL ABC (PHP)	BID PRICE AS READ (PHP)
1	Prednisone	17,500	Tablet	43,225.00	43,225.00

WHEREAS, MDI JV with IHMC was declared as the single bidder as read subject to further review and correction of the financial bid, if necessary;

WHEREAS, on 25 February 2021, the detailed evaluation of the legal, financial and technical aspects of the submitted proposals of MDI JV with IHMC was undertaken by the designated TWG;

WHEREAS, the TWG-Financial Evaluator submitted the Abstract of Quotations as Calculated, to wit:

Item No. 1 – 17,500 tablets of Prednisone

Rank	Name of Company	Total ABC (PhP)	Bid as Calculated Amount (PhP)	% Variance from ABC
Single Calculated Quotation (SCQ)	MDI JV with IHMC	43,225.00	43,225.00	0.00%

WHEREAS, on the same date, the TWG Legal and Financial found the bid of MDI JV with IHMC “Complying” with the requirements and submitted their respective reports;

WHEREAS, on 02 March 2021, the TWG Technical found the bid of MDI JV with IHMC for clarification on the Sworn Statement;

WHEREAS, on 03 March 2021, the TWG reports were presented to the COBAC-A during its 10th Regular Meeting. The Secretariat informed the COBAC-A that Sworn Statement is not a requirement in the RFQ, and the TWG Technical informed the Secretariat that he will revise his report. Upon review and deliberation, the Committee concurred with the TWG recommendation to recommend award of contract to MDI JV with IHMC, subject to the submission of the revised report of the TWG Technical;

WHEREAS, on 09 March 2021, the TWG Technical submitted its revised report citing MDI JV with IHMC “Complying” with the requirements;


WHEREAS, on 10 March 2021, the revised TWG-Technical evaluation report was presented to the COBAC-A during its 11th Regular Meeting. Upon review and deliberation, the Committee instructed to proceed with the remaining procurement process and recommend award of contract to MDI JV with IHMC;

NOW THEREFORE, on the basis of the above, the herein members of the COBAC-A **HEREBY RESOLVE** to recommend the award of contract to **Metro Drug Joint Venture with Interpharma Holdings Management Corp.**/determined as the Single Calculated and Responsive Quotation /with a total Contract Price of Forty Three Thousand Two Hundred Twenty Five Philippine Pesos (PhP43,225.00) /inclusive of local taxes for the item listed below:

Item No.	Particular	Quantity	Unit	Total Bid Price (PhP)
1	Prednisone /	17,500 /	Tablets /	43,225.00 /

Signed this 24 day of MAR 2021 at the Department of Health, San Lazaro Compound, Sta. Cruz, Manila.

CENTRAL OFFICE BIDS AND AWARDS COMMITTEE (COBAC) - A


LESTER M. TAN, MD
 Regular Member


(Absent) /
ALELI ANNIE GRACE P. SUDIACAL, MD, MPH, CESE
 Regular Member


LEONITA P. GORGOLON, MD, MHA, MCHM, CEO VI
 Regular Member

(Absent) /
MARIA SOLEDAD Q. ANTONIO, MD, PhD, MPH, DPAFP, CESE
 Vice-Chairperson

NESTOR F. SANTIAGO, JR., MD, MPH, MCHM, MCHM, CESO II
 Assistant Secretary of Health
 Chairperson

By Authority of the Secretary of Health:


BEVERLY LORRAINE C. HO, MD, MPH /
 Director IV
 Disease Prevention and Control Bureau

APR 12 2021